Literature DB >> 2016689

The spectrum of Mycobacterium kansasii disease associated with HIV-1 infected patients.

G T Valainis1, L M Cardona, D L Greer.   

Abstract

Louisiana is known to be an area endemic for Mycobacterium kansasii (MK). Since MK tends to disseminate in immunocompromised patients, one might, therefore, expect to observe an increasing number of MK infections associated with human immunodeficiency virus (HIV-1). A systematic 60-month review of clinical, microbiologic, and radiographic data associated with MK was performed from two major referral centers in New Orleans. From June 30, 1983 through June 30, 1988, MK was isolated from 72 patients. Twenty-three of the 72 (31.9%) were found to be coinfected with HIV-1. Over the 5-year study period, the phenomenon of dual infection increased from 0 to 50%. Six cases of extrapulmonary infection were found among the HIV-1 patients as compared to 1 in 49 non-HIV patients (p = 0.003, Fisher's exact test). In addition, patients with dual infection had atypical chest radiographs, usually with interstitial infiltrates without cavitation. Most of these patients died within 12 months (90.9%). When treatment was administered at all, often it varied considerably from patient to patient despite the well-known in vitro efficacy of certain widely available anti-mycobacterial agents.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2016689

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  8 in total

1.  Comparison of a Novel Regimen of Rifapentine, Tedizolid, and Minocycline with Standard Regimens for Treatment of Pulmonary Mycobacterium kansasii.

Authors:  Moti Chapagain; Tawanda Gumbo; Scott K Heysell; Shashikant Srivastava
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

2.  Nasal Mycobacterium kansasii infection in a patient with acquired immunodeficiency syndrome.

Authors:  E Tortoli; M T Simonetti; D Dionisio
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-07       Impact factor: 3.267

3.  Mycobacterium kansasii: its presentation, treatment and outcome in HIV infected patients.

Authors:  G Rooney; M R Nelson; B Gazzard
Journal:  J Clin Pathol       Date:  1996-10       Impact factor: 3.411

4.  Omadacycline Pharmacokinetics/Pharmacodynamics in the Hollow Fiber System Model and Potential Combination Regimen for Short Course Treatment of Mycobacterium kansasii Pulmonary Disease.

Authors:  Sanjay Singh; Tawanda Gumbo; Gunavanthi D Boorgula; Prem Shankar; Scott K Heysell; Shashikant Srivastava
Journal:  Antimicrob Agents Chemother       Date:  2022-08-17       Impact factor: 5.938

5.  Activities of azithromycin and clarithromycin against nontuberculous mycobacteria in beige mice.

Authors:  S P Klemens; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

6.  False-positive Gen-Probe direct Mycobacterium tuberculosis amplification test results for patients with pulmonary M. kansasii and M. avium infections.

Authors:  J H Jorgensen; J R Salinas; R Paxson; K Magnon; J E Patterson; T F Patterson
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

7.  Tentative evidence of AIDS-associated biotype of Mycobacterium kansasii.

Authors:  E Tortoli; M T Simonetti; C Lacchini; V Penati; P Urbano
Journal:  J Clin Microbiol       Date:  1994-07       Impact factor: 5.948

8.  Activation of an NLRP3 inflammasome restricts Mycobacterium kansasii infection.

Authors:  Chang-Chieh Chen; Sheng-Hui Tsai; Chia-Chen Lu; Shiau-Ting Hu; Ting-Shu Wu; Tsung-Teng Huang; Najwane Saïd-Sadier; David M Ojcius; Hsin-Chih Lai
Journal:  PLoS One       Date:  2012-04-30       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.